Approved Study Database
| Ref. No. | Scientific Title | Principal investigator |
|---|---|---|
| 2016.194 | Phase II clinical study on the safety and efficacy of Antireflux Mucosectomy (ARMS) for treatment of Gastroesophageal Reflux Disease |
Prof. CHIU Philip Wai Yan 趙偉仁 |
| 2017.247 | Phase Ib study of PDR001 in combination with regorafenib in adult patients with previously treated metastatic microsatellite stable (MSS) colorectal cancer |
Prof. MA Brigette Buig Yue 馬碧如教授 |
| 2008.395 | Phase I/II Study of Temsirolimus (Torisel) as Novel Therapeutic Drug for Patients with Unresectable Hepatocellular Carcinoma (HCC) - A Correlative Study with Stathmin Over-expression | Prof. YEO Winnie |
| 2007.095 | Phase I/II Study of Paclitaxel/ Carboplatin/ RAD001 as First Line Therapy for Advanced Adenocarcinoma of the Stomach | Prof. YEO Winnie |
| 2015.152 | Phase I/II study of aflibercept and the modified XELIRI regimen in the second-line treatment of metastatic colorectal cancer | Prof. MA Brigette |
| 2010.399 | Phase I, open label, randomized study to examine the pharmacokinetics, safety and tolerability of different oral doses of TMC435 after single and repeated dosing in healthy Chinese subjects | Prof. Tomlinson Brian |
| 2005.456 | Phase I Study on the Study and Pharmacokinetics of Single and Repeated Application of IMD-0354 in Health Male Volunteers | Prof. Brian Tomlinson |
| 2005.148 | Phase I Study on the Safety and Pharmacokinetics of IMD-1041 in Healthy Male Volunteers | Prof. Brian Tomlinson |
| 2013.638 | Phase I clinical trial on intra-operative local supplementation of vitamin C irrigation saline during anterior cruciate ligament reconstruction | Prof. YUNG Patrick Shu Hang |
| 2015.065 | Phase 3b/4 Randomized Safety Endpoint Study Of 2 Doses Of Tofacitinib In Comparison To A Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis | Prof. TAM Lai Shan |
| 2008.364 | Phase 3b, Randomized, Open-Label Study of Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa as First-line Treatment in Subjects with Advanced Renal Cell Carcinoma | Dr. Ho Wing Ming |
| 2024.660 | Phase 3b, Open-label, Multicenter, Single-dose Study Investigating Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy Administered to Adult Subjects with Severe or Moderately Severe Hemophilia B with Detectable Pretreatment AAV5 Neutralizing Antibodies | Dr. WONG Raymond Siu Ming |
| 2009.596 | Phase 3, Randomized, Open-label Study of the Efficacy and Safety of PF-02341066 Versus Standard of Care Chemotherapy (Pemetrexed or Docetaxel) in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Harboring a Translocation or Inversion Event Involv | MOK S K Tony |
| 2011.217 | Phase 3, randomized, open-label study of the efficacy and safety of crizotinib versus pemetrexed/cisplatin or pemetrexed/carboplatin in previously untreated patients with non-squamous carcinoma of the lung harboring a translocation or inversion event involving the anaplastic lymphoma kinase (ALK) gene locus | Prof. MOK Tony S. K. |
| 2012.473 | PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF THE EFFICACY AND SAFETY OF CRIZOTINIB VERSUS PEMETREXED/CISPLATIN OR PEMETREXED/CARBOPLATIN IN PREVIOUSLY UNTREATED EAST ASIAN PATIENTS WITH NON-SQUAMOUS CARCINOMA OF THE LUNG HARBORING A TRANSLOCATION OR INVERSION EVENT INVOLVING THE ANAPLASTIC LYMPHOMA KINASE (ALK) GENE LOCUS | Prof. MOK Tony Shu Kam |
| 2015.631 | Phase 3, prospective, randomized, multi-center clinical study comparing the safety and efficacy of BAX 855 following PK-guided prophylaxis targeting two different FVIII trough levels in subjects with severe Hemophilia A |
Dr. LI Chi Kong 李志光醫生 |
| 2015.670 | Phase 3, prospective, randomized, multi-center clinical study comparing the safety and efficacy of BAX 855 following PK-guided prophylaxis targeting two different FVIII trough levels in subjects with severe Hemophilia A |
Dr. WONG Raymond Siu Ming 王紹明醫生 |
| 2016.247 | Phase 3, prospective, multi-center, open label study to investigate safety, immunogenicity, and hemostatic efficacy of PEGylated Factor VIII (BAX 855) in previously untreated patients (PUPs) < 6 years with severe hemophilia A (FVIII < 1%) |
Dr. LI Chi Kong 李志光 |
| 2016.565 | Phase 3, Multicenter, Randomized, Double-blind, placebo-controlled, parallel-group, efficacy and safety study comparing EG-1962 to standard of care oral Nimodipine in adults with aneurysmal subarachnoid hemorrhage. |
Prof. POON Wai Sang 潘偉生 |
| 2025.019 | Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of JNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis | Prof. TAM Lai Shan |
| 2023.369 | Phase 3 Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of MK-0616 in Reducing Major Adverse Cardiovascular Events in Participants at High Cardiovascular Risk | Prof. LUK Andrea On Yan |
| 2021.399 | PHASE 3 RANDOMIZED STUDY OF DS-1062A VERSUS DOCETAXEL IN PREVIOUSLY TREATED ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WITH OR WITHOUT ACTIONABLE GENOMIC ALTERATIONS (TROPION-LUNG01) |
Dr LOONG Herbert Ho Fung 龍浩鋒 |
| 2022.552 | Phase 3 Multicenter, Randomized, Double-Blind, Study to Assess the Efficacy and Safety of Treatment with Bepirovirsen in Nucleos(t)ide Analogue-treated Participants with Chronic Hepatitis B Virus (B-Well 1) |
Prof. WONG Grace Lai Hung 黃麗虹 |
| 2009.638 | Phase 2, Open-label, Single Arm Study of the Efficacy and Safety of PF-02341066 in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Harboring A Translocation or Inversion Involving the Anaplastic Lymphoma Kinase (ALK) Gene Locus | Prof. MOK Tony S. K. |
| 2024.358 | Phase 2 study on safety and efficacy of irreversible electroporation for locally advanced pancreatic malignancy | Prof. CHOK Siu Ho |
| 2013.256 | Phase 2 study on safety and efficacy of irreversible electroporation for inoperable hepatic and pancreatic malignancy | Prof. YU Simon |
| 2006.310 | Phase 2 Study of SU011248 in Patients with Recurrent or Metastatic Nasopharyngeal Carcinoma | Prof. Chan T.C. Anthony |
| 2024.379 | Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements | Prof. CHAN Stephen Lam |
| 2010.253 | Phase 2 Study of Axitinib in Patients with Recurrent or Metastatic Nasopharyngeal Carcinoma | Prof. CHAN Anthony |
| 2021.280 | Phase 1b/2 Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia |
Prof. LI Chi Kong 李志光 |
| 2018.123 | Phase 1b/2 Safety, Pharmacokinetic, and Efficacy Study of G1T38 in Combination with Osimertinib in Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer (NSCLC) |
Prof. MOK Tony Shu Kam 莫樹錦 |
| 2017.661 | PHASE 1/2 STUDY OF TAS-120 IN PATIENTS WITH ADVANCED SOLID TUMORS HARBORING FGF/FGFR ABERRATIONS |
Dr. CHAN Stephen Lam 陳林醫生 |
| 2014.528 | Phase 1/2 Study of PF-06463922 (An ALK/ROS1 Tyrosine Kinase Inhibitor) in Patients with Advanced Non-Small Cell Lung Cancer Harboring Specific Molecular Alterations | Prof. MOK Tony Shu Kam |
| 2019.342 | Phase 1/2 Dose-Escalation and Expansion Study of FLX475 Alone and in Combination with Pembrolizumab in Advanced Cancer |
Prof. MA Brigette Buig Yue 馬碧如教授 |
| 2007.312 | Phase 1 Study of OPB-31121 in Patients with Relapsed or Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma | Dr. Lei I.K. Kenny |
| 2010.596 | Phase 1 Randomised study to assess immunogenicity, reactogenecity, safety and tolerability of two pneumococcal conjugate vaccines administered intraderamlly and intramuscularly to adults aged 20 to 50 years | Prof NELSON Edmund A.S. |
| 2024.106 | Phase 1 randomised controlled clinical trial testing the safety and efficacy of CPP-anti-VEGF for the treatment of neovascular age-related macular degeneration | Dr. BRELEN Mårten Erik |
| 2012.337 | Phase 1 Clinical Trial to Establish the Safety and Feasibility of Brain Transplants of Umbilical Cord Blood Mononuclear Cells in Chronic Ischemic Stroke | Prof. POON Wai Sang |
| 2018.582 | Pharmacological Treatment of Mitochondrial Dysfunction in Diabetic Kidney Disease |
Prof. SZETO Cheuk Chun 司徒卓俊 |
| 2008.180 | Pharmacokinetics, Pharmacogenomics and Toxicity of Efavirenz in Chinese Patients with HIV Infection | Prof. LEE Shui Shan |
| 2016.263 | Pharmacokinetics study of Trazodone Hydrochloride Prolonged-release tablets in Chinese Healthy Volunteers | Dr. LUK Andrea On Yan |
| 2006.462 | Pharmacokinetics of Single and Repeated Oral Administration of S 33138 20 mg Daily in Chinese Healthy Male and Female Volunteers | Prof. Tomlinson Brian |
| 2005.370 | Pharmacokinetics of Single and Repeated Oral Administration of S 18886 30mg Daily in Chinese Healthy Male Volunteers | Prof. Brian Tomlinson |
| 2011.158 | Pharmacokinetics of Oseltamivir in Adult Chinese Hospitalized for Severe Influenza Infection and its Impact on Viral Clearance | Dr Lee Nelson |
| 2020.284 | Pharmacokinetics and safety profile of Apixaban in patients with peritoneal dialysis |
Dr. FUNG Winston Wing Shing 馮永丞 |
| 2023.034 | Pharmacokinetic study of vancomycin and meropenem and a pilot paediatric antibiotic stewardship program |
Prof. NG Wai Yin 吳煒燕 |
| 2013.407 | Pharmacokinetic study of once-daily formulation of Tacrolimus (Advagraf_) in Chinese kidney transplant patients | Dr Ma King Wing, Terry |
| 2007.452 | Pharmacokinetic Study of Doxorubicin Delivered Through Transarterial Administered of Four Different Doxorubicin-Loaded Formulations for Hepatocellular Carcinoma | Dr Yu Simon |
| 2011.390 | Pharmacokinetic interaction between rosuvastatin and telmisartan | Prof. TOMLINSON Brian |
| 2019.688 | Pharmacokinetic and pharmacodynamic study of a novel sublingual aspirin tablet compared to conventional oral aspirin in healthy subjects | Prof. CHOW Elaine |
Page 79 of 262.